US Markets

VBI Vaccines selects two COVID-19 vaccine candidates for human trials

Credit: REUTERS/DADO RUVIC

VBI Vaccines Inc said on Wednesday it expected to begin human testing of two of its experimental COVID-19 vaccine candidates at the end of the year.

Aug 26 (Reuters) - VBI Vaccines Inc VBIV.O said on Wednesday it expected to begin human testing of two of its experimental COVID-19 vaccine candidates at the end of the year.

The two candidates, VBI-2901 and VBI-2902, were selected after three pre-clinical mouse studies induced neutralizing antibodies after a single dose, the company said.

The activity was analyzed using a plaque reduction neutralization test, considered the gold standard for measuring antibodies that can neutralize a virus, the company said.

VBI said its manufacturing partner, Therapure Biomanufacturing, will begin making bulk vaccines in September for use through mid-stage trials.

VBI, which was this month awarded C$56 million ($42 million) by the Canadian government to accelerate its COVID-19 vaccine development program, is one of the many companies racing to produce a safe and effective vaccine against the virus.

Many vaccine candidates are already in later stage of development.

Shares of the company rose 3.8% before the bell.

($1 = 1.32 Canadian dollars)

(Reporting by Dania Nadeem in Bengaluru; Editing by Sriraj Kalluvila)

((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3463;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

VBIV

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More